These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Infectious disease. An enterprising time for HIV vaccine research. Cohen J Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300 [No Abstract] [Full Text] [Related]
3. RV144: old vs. new. Weiner DB Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335 [No Abstract] [Full Text] [Related]
4. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
5. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Koff WC Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891 [TBL] [Abstract][Full Text] [Related]
6. AIDS research. Novel antibody response may explain HIV vaccine success. Cohen J Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167 [No Abstract] [Full Text] [Related]
7. New mouse models provide insights into how to design a more effective HIV vaccine. Harper KN AIDS; 2017 Jan; 31(3):N3-N4. PubMed ID: 28002067 [No Abstract] [Full Text] [Related]
8. In pursuit of an HIV vaccine: an interview with Andrew McMichael. McMichael AJ BMC Biol; 2013 May; 11():60. PubMed ID: 23692824 [No Abstract] [Full Text] [Related]
9. HIV vaccine development--improving on natural immunity. Johnston MI; Fauci AS N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447 [No Abstract] [Full Text] [Related]
10. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines. Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483 [TBL] [Abstract][Full Text] [Related]
11. [The new vaccine challenges of "humanization" of HIV]. Nau JY Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395 [No Abstract] [Full Text] [Related]
12. An HIV vaccine--evolving concepts. Johnston MI; Fauci AS N Engl J Med; 2007 May; 356(20):2073-81. PubMed ID: 17507706 [No Abstract] [Full Text] [Related]
13. In vivo protection by broadly neutralizing HIV antibodies. van Gils MJ; Sanders RW Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020 [TBL] [Abstract][Full Text] [Related]
14. Prospects for a Globally Effective HIV-1 Vaccine. Excler JL; Robb ML; Kim JH Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431 [TBL] [Abstract][Full Text] [Related]
15. HIV vaccine design: the neutralizing antibody conundrum. Stamatatos L Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693 [No Abstract] [Full Text] [Related]
16. HIV neutralizing antibodies reignite interest in vaccine. Waltz E Nat Biotechnol; 2012 Mar; 30(3):204-5. PubMed ID: 22398603 [No Abstract] [Full Text] [Related]
17. [Vaccination against HIV to arouse cellular immunity]. Kallings LO Lakartidningen; 2003 Jun; 100(25):2200-1. PubMed ID: 12872507 [No Abstract] [Full Text] [Related]
18. A brief history of the global effort to develop a preventive HIV vaccine. Esparza J Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164 [TBL] [Abstract][Full Text] [Related]